FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Can Vet J / Use of lomustine (CCNU) in a case of cutaneous equine lympho...
The Canadian veterinary journal = La revue veterinaire canadienne2013; 54(12); 1137-1141;

Use of lomustine (CCNU) in a case of cutaneous equine lymphoma.

Abstract: A 12-year-old gelding was diagnosed with recurrent lymphoma in multiple cutaneous sites. A highly invasive preputial mass caused urethral obstruction. The horse was treated with surgery and chemotherapy consisting of lomustine (CCNU) and prednisolone. The treatment was well-tolerated and effective. This is the first reported use of lomustine (CCNU) in a horse for the treatment of equine lymphoma. Utilisation de lomustine (CCNU) dans un cas de lymphone cutané équin. Un hongre âgé de 12 ans a été diagnostiqué avec un lymphome récurrent sur plusieurs sites cutanés. Une masse préputiale hautement invasive causait une obstruction urétrale. Le cheval a été traité par chirurgie et chimiothérapie composée de lomustine (CCNU) et de prednisolone. Le traitement a été efficace et bien toléré. Il s’agit de la première utilisation signalée de la lomustine (CCNU) chez un cheval pour le traitement d’un lymphome équin.(Traduit par Isabelle Vallières).
Get Full Text
Publication Date: 2013-12-03 PubMed ID: 24293673PubMed Central: PMC3831386
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Case Reports
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article outlines the successful treatment of recurrent lymphoma in a horse using surgery and chemotherapy with lomustine (CCNU) and prednisolone. This is the first reported successful use of lomustine in a horse for this purpose.

Introduction and Case Details

  • The subject of the study was a 12-year-old gelding (a castrated horse) which was diagnosed with lymphoma affecting multiple parts of its skin.
  • An aggressively invasive mass on the sheath enclosing the penis (preputial mass) was causing a blockage of the urinary tube (urethral obstruction).

Therapeutic Approach

  • The horse was treated with two main therapeutic modalities – surgery and chemotherapy.
  • The surgical intervention presumably aimed at removing the greatest possible amount of the cancerous tissue, including the obstructive preputial mass.
  • The chemotherapy regimen utilized two drugs – lomustine (CCNU) and prednisolone.
  • Lomustine is a type of chemotherapy drug termed an alkylating agent which works by damaging the DNA of rapidly dividing cells, such as cancer cells, thus hampering their proliferation.
  • Prednisolone is a glucocorticoid hormone which can restrain immune responses and inflammation, and is also known to have beneficial effects in some cases of cancer.

Treatment Outcome

  • The treatment was reported to be well-tolerated by the horse, indicating a lack of severe or unmanageable side-effects related to the chemotherapy or surgery.
  • The treatments were also indicated to be effective, suggesting a reduction in cancer burden and potentially amelioration of the horse’s condition or prognosis.

Significance

  • This case marks the first reported instance of a horse being successfully treated for lymphoma with the use of lomustine. The results suggest that lomustine could be a viable component of therapeutic regimens for equine lymphoma in future.
  • These findings also contribute to the limited body of knowledge on therapy options for lymphoma in horses.

Cite This Article

APA
Doyle AJ, MacDonald VS, Bourque A. (2013). Use of lomustine (CCNU) in a case of cutaneous equine lymphoma. Can Vet J, 54(12), 1137-1141.

Publication

The Canadian veterinary journal = La revue veterinaire canadienne
ISSN: 0008-5286
NlmUniqueID: 0004653
Country: Canada
Language: English
Volume: 54
Issue: 12
Pages: 1137-1141

Researcher Affiliations

Doyle, Aimie J
  • Department of Health Management (Doyle) and Department of Pathology and Microbiology (Bourque), Atlantic Veterinary College, University of Prince Edward Island, 550 University Avenue, Charlottetown, Prince Edward Island C1A 3P4, and Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, Saskatchewan S7N 5B4 (MacDonald).
MacDonald, Valerie S
    Bourque, Andrea

      MeSH Terms

      • Animals
      • Antineoplastic Agents, Alkylating / therapeutic use
      • Antineoplastic Agents, Hormonal / therapeutic use
      • Drug Therapy, Combination
      • Foreskin / surgery
      • Horse Diseases / drug therapy
      • Horse Diseases / surgery
      • Horses
      • Lomustine / therapeutic use
      • Lymphoma / drug therapy
      • Lymphoma / surgery
      • Lymphoma / veterinary
      • Male
      • Prednisolone / therapeutic use
      • Skin Neoplasms / drug therapy
      • Skin Neoplasms / surgery
      • Skin Neoplasms / veterinary
      • Urethral Obstruction / etiology
      • Urethral Obstruction / surgery
      • Urethral Obstruction / veterinary

      References

      This article includes 21 references
      1. Allen D. Conditions of the penis and prepuce.. In: Wolfe DF, Moll HD, editors. Large Animal Urogenital Surgery. Baltimore, Maryland: Williams & Wilkins; 1998. pp. 55–62.
      2. Aleman M. Lymphoma in horses.. In: Smith BP, editor. Large Animal Internal Medicine. 4th ed. St. Louis, Missouri: Mosby; 2009. pp. 1176–1179.
      3. Scott DW, Miller WH. Equine Dermatology.. St. Louis, Missouri: Elsevier; 2011. Neoplasms, cysts, hamartomas, and keratoses; pp. 468–516.
      4. deBruijn CM, Veenman JN, Rutten VPMG. Clinical, histopathological and immunophenotypical findings in five horses with cutaneous malignant lymphoma.. Res Vet Sci 2007;83:63–72.
        pubmed: 17174365
      5. Kelley LC, Mahaffey EA. Equine malignant lymphomas: Morphologic and immunohistochemical classification.. Vet Pathol 1998;35:241–252.
        pubmed: 9684967
      6. Henson KL, Alleman AR, Kelley LC. Immunohistochemical characterization of estrogen and progesterone receptors in lymphoma of horses.. Vet Clin Pathol 2000;29:40–46.
        pubmed: 12070809
      7. Meyer J, Delay J, Bienzle D. Clinical, laboratory, and histopathologic features of equine lymphoma.. Vet Pathol 2006;43:914–924.
        pubmed: 17099148
      8. Durham AC, Pillitteri CA, San Myint M. Two hundred three cases of equine lymphoma classified according to the World Health Organization (WHO) classification criteria.. Vet Pathol 2013;50:86–93.
        pubmed: 22700849
      9. Saulez MN, Schlipf JW, Debra CK. Use of chemotherapy for treatment of a mixed-cell thoracic lymphoma in a horse.. J Am Vet Med Assoc 2004;224:733–738.
        pubmed: 15002812
      10. Byrne BA, Yvorchuk-St Jean K, Couto CG. Successful management of lymphoproliferative disease in two pregnant mares.. Vet Cancer Soc Proc 1991:8.
      11. Hurcombe SDA, Slovis NM, Kohn CW. Poorly differentiated leiomyosarcoma of the urogential tract in a horse.. J Am Vet Med Assoc 2008;233:1908–1912.
        pubmed: 19072607
      12. Littlewood JD, Whitwell KE, Day MJ. Equine cutaneous lymphoma: A case report.. Vet Derm 1995;6:105–111.
        pubmed: 34644860
      13. Gollagher RD, Ziola B, Chelack BJ. Immunotherapy of equine cutaneous lymphosarcoma using low dose cyclophosphamide and autologous tumour cells infected with vaccine virus.. Can Vet J 1993;34:371–373.
        pmc: PMC1686569pubmed: 17424244
      14. Gerson SL, Bulgar AD, Weeks LD, Chabner BA. Alkylating agents.. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy: Principles and Practice. 5th ed. Philadelphia, Pennsylvania: Lippincott Williams and Wilkins; 2011. pp. 267–309.
      15. Fontaine J, Bovens C, Bettenay S. Canine cutaneous epitheliotropic T-cell lymphoma: A review.. Vet Comp Onc 2009;5:454–461.
        pubmed: 19222826
      16. Vail DM, Young KM. Canine lymphoma and lymphoid leukemia.. In: Withrow SJ, Vail DM, editors. Withrow and MacEwen’s Small Animal Clinical Oncology. 4th ed. St. Louis, Missouri: Saunders; 2007. pp. 699–732.
      17. Risbon RE, deLorimier LP, Skorupski K. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999–2004). J Vet Intern Med 2006;20:1389–1397.
        pubmed: 17186855
      18. Williams LE, Rassnick KIM, Power HT. CCNU in the treatment of canine epitheliotropic lymphoma.. J Vet Intern Med 2006;20:136–143.
        pubmed: 16496933
      19. Fontaine J, Heimann M, Day MJ. Canine cutaneous epitheliotropic T-cell lymphoma: A review of 30 cases.. Vet Derm 2009;3:267–275.
        pubmed: 20141606
      20. De Bosschere H, Declercq J. Cutaneous nonepitheliotropic B-cell lymphoma in a Golden retriever.. Vlaams Diergeneeskundig Tijdschrift 2008;77:315–318.
      21. Komori S, Nakamura S, Takahashi K. Use of lomustine to treat cutaneous nonepitheliotropic lymphoma in a cat.. J Am Vet Med Assoc 2005;226:237–239.
        pubmed: 15706974

      Citations

      This article has been cited 1 times.
      1. Luethy D, Frimberger AE, Bedenice D, Byrne BS, Groover ES, Gardner RB, Lewis T, MacDonald VS, Proctor-Brown L, Tomlinson JE, Rassnick KM, Johnson AL. Retrospective evaluation of clinical outcome after chemotherapy for lymphoma in 15 equids (1991-2017). J Vet Intern Med 2019 Mar;33(2):953-960.
        doi: 10.1111/jvim.15411pubmed: 30636061google scholar: lookup
      Subscribe to our newsletter
      Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.